Testing effectiveness (Phase 2)WithdrawnNCT05371860
What this trial is testing
Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response
Who this might be right for
Breast CancerHER2-positive Breast Cancer
Armando Giuliano